By Tom Rosenthal
Islatravir (ISL, Merck), an investigational first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTTI), appears safe and effective when combined with doravirine (DOR; Pifeltro, Merck) for HIV, according to research presented at the 2019 International AIDS Society Conference of HIV Science (IAS 2019), in Mexico City (abstract 4789).
Islatravir combined with DOR—a next-generation non-nucleoside reverse transcriptase inhibitor—appears to be